Uses of antagonists of hyaluronan signaling

US9717752B2 · kind B2 · utility

Assignees

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US
• Duke University · US
• The University of North Carolina at Chapel Hill · US

Inventors

• Stavros Garantziotis · Chapel Hill, US
• John W. Hollingsworth · Durham, US
• Bryan P. Toole · Fairfax, US
• Jian Liu · Los Angeles, US

Key dates

• Filing date: Mar 8, 2013
• Grant date: Aug 1, 2017
• Expiry date: Jun 7, 2033

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K31/715
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Described herein is the finding that hyaluronan antagonists that inhibit hyaluronan signaling are capable of inhibiting airway inflammation and airway hyperresponsiveness (AHR). The present disclosure provides a method of preventing or reducing AHR in a subject suffering from or at risk for AHR by administering a hyaluronan antagonist. Also provided is a method of treating an airway disease or disorder in a subject by administering a hyaluronan antagonist. Hyaluronan antagonists include, for example, heparosan and hyaluronan oligosaccharides (oHAs). In some embodiments, the hyaluronan antagonist is administered locally to the airway, such as with an inhaler or nebulizer.